BDR Pharma has launched India’s first Generic- Midostaurin under the brand name MSTARIN, which is indicated in rare, hard-to-treat cancers, the company notified via a statement.
The statement also said that the drug is approved for use in combination with standard Daunorubicin and Cytarabine induction, and high- dose Cytarabine consolidation chemotherapy, and for patients in complete response followed by Midostaurin single-agent maintenance therapy for adults with newly-diagnosed Acute Myeloid Leukemia (AML) who are FLT3 mutation-positive.
The drug will be available in the form of capsules, it concluded.